Published in Int J Cancer on March 31, 1999
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res (2008) 2.01
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun (2007) 1.96
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene (2011) 1.42
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer (2001) 1.17
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol (2005) 1.15
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun (2014) 1.09
Retinoblastoma loss modulates DNA damage response favoring tumor progression. PLoS One (2008) 0.88
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer (2004) 0.87
Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res (2010) 0.84
Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia. Br J Cancer (2004) 0.82
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol (2012) 0.76
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys (2010) 0.76
Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor. Curr Pharm Des (2015) 0.75
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res (1993) 3.59
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature (1996) 3.40
Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A (1972) 3.24
Appearance of T-cell markers in bone marrow rosette-forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci U S A (1971) 3.13
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells. Eur J Immunol (1972) 2.34
Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst (1994) 2.25
Divergent orientation of transcription from the biotin locus of Escherichia coli. J Mol Biol (1971) 2.18
Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg (1998) 2.17
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev (2001) 2.16
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell (1974) 2.12
Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene (1997) 1.95
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84
Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. J Immunol (1971) 1.80
Controls and polarity of transcription during bacteriophage T4 development. J Mol Biol (1971) 1.77
Fractionation of the complementary strands of coliphage T4 DNA based on the asymmetric distribution of the poly U and poly U,G binding sites. Virology (1968) 1.75
Ontogenesis of cell-mediated immunity in murine thymocytes and spleen cells and its acceleration by thymosin, a thymic hormone. J Immunol (1971) 1.73
Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A (1987) 1.71
Concurrent colorectal malignancy and abdominal aortic aneurysm: a multicentre experience and review of the literature. Eur J Vasc Endovasc Surg (2009) 1.71
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol (1992) 1.66
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66
A cancer therapy resistant to resistance. Nature (1997) 1.65
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer (1997) 1.48
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45
Orientation and control of transcription in E. coli phage lambda. Nature (1969) 1.43
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res (2000) 1.42
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res (1988) 1.36
Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum. Cell Immunol (1974) 1.35
Conservative management of vestibular schwannomas: third review of a 10-year prospective study. Clin Otolaryngol (2008) 1.33
Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol (1983) 1.32
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis (2008) 1.31
An inhibitory monoclonal antibody against human tissue factor. Blood (1987) 1.30
Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol (1993) 1.29
Establishing a link between oncogenes and tumor angiogenesis. Mol Med (1998) 1.29
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27
In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest (1996) 1.26
Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat (2008) 1.25
Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology (2002) 1.25
Transcriptional controls in developing bacteriophages. J Cell Physiol (1969) 1.25
Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer (1978) 1.24
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res (2000) 1.24
Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med (1989) 1.23
Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J (2001) 1.23
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Orientation of transcription for the galactose operon as determined by hybridization of gal mRNA with the separated DNA strands of coliphages lambda-dg. J Mol Biol (1968) 1.21
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20
Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol (1995) 1.20
Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Curr Biol (1998) 1.20
Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry (1992) 1.20
Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (1996) 1.20
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res (1998) 1.20
Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care (1999) 1.18
Cell adhesion and drug resistance in cancer. Curr Opin Oncol (1997) 1.18
Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene (1996) 1.18
Origin of chemiluminescence accompanying the reaction of the 9-cyano-10-methylacridinium cation with hydrogen peroxide. J Org Chem (2004) 1.18
'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer (2000) 1.18
Identification of active tissue factor in human coronary atheroma. Circulation (1996) 1.18
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17
Measurement of direct photon production in p+p collisions at sqrt[s] = 200 GeV. Phys Rev Lett (2007) 1.16
Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology (1997) 1.14
Spontaneous in vitro transformation of human fibroblasts. J Natl Cancer Inst (1984) 1.14
Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer (1975) 1.14
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14
Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery (1998) 1.13
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene (2000) 1.12
Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest (1993) 1.12
Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett (2010) 1.12
Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol (1993) 1.12
Particle-yield modification in jetlike azimuthal dihadron correlations in Pb-Pb collisions at √s(NN)=2.76 TeV. Phys Rev Lett (2012) 1.11
An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst (1976) 1.11
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10